Literature DB >> 116778

Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials.

J S Penta, M Rozencweig, A M Guarino, F M Muggia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 116778     DOI： 10.1007/bf00254979

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  4 in total

1.  Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: protocols of the laboratory of toxicology.

Authors:  D J Prieur; D M Young; R D Davis; D A Cooney; E R Homan; R L Dixon; A M Guarino
Journal:  Cancer Chemother Rep 3       Date:  1973-01

2.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05

3.  Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man.

Authors:  E R Homan
Journal:  Cancer Chemother Rep 3       Date:  1972-05

4.  Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.

Authors:  M A Goldsmith; M Slavik; S K Carter
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701
  4 in total
  11 in total

Review 1.  Choice of starting dose and escalation for phase I studies of antitumor agents.

Authors:  J S Penta; G L Rosner; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.

Authors:  Nicolas Penel; Alain Duhamel; Antoine Adenis; Patrick Devos; Nicolas Isambert; Stéphanie Clisant; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2010-11-04       Impact factor: 3.850

3.  Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials.

Authors:  Nicolas Penel; Pierre Leblond; Amélie Lansiaux; Stéphanie Clisant; Eric Dansin; Antoine Adenis; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2009-09-16       Impact factor: 3.850

4.  Phase I trials in clinical oncostatic pharmacology.

Authors:  P Ribaud; G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Antitumor drug toxicity in tumor-free and tumor-bearing mice.

Authors:  S D Harrison; H D Giles; E P Denine
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology.

Authors:  P J Bugelski; U Atif; S Molton; I Toeg; P G Lord; D G Morgan
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

7.  Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.

Authors:  M R Nowrousian; C G Schmidt
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

8.  The war on cancer: have we won the battle but lost the war?

Authors:  Rachel Brennan; Sara Federico; Michael A Dyer
Journal:  Oncotarget       Date:  2010-06

9.  Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.

Authors:  Charles Ferte; Jean-Charles Soria; Nicolas Penel
Journal:  PLoS One       Date:  2011-03-02       Impact factor: 3.240

10.  Effects of cisplatin on different haemopoietic progenitor cells in mice.

Authors:  M R Nowrousian; C G Schmidt
Journal:  Br J Cancer       Date:  1982-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.